Physician profile
Polina Aron
NPI 1164086252
$618.90
in general payments reported to CMS, 2019-2025
10 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $147 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.83 | 2024 | Evenity |
| Dexcom, INC. | $108.10 | 2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $107.71 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $90.82 | 2025 | Minimed 780g |
| Lilly USA, LLC | $67.61 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $50.83 | 2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $21.91 | 2025 | |
| Sequel Med Tech, LLC | $20.04 | 2025 | Twiist |
| Abbott Laboratories | $19.99 | 2025 | Freestyle Libre |
| Ascendis Pharma Endocrinology INC | $17.06 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polina Aron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.